It seems like Furman's vision was to spin off the offshore stuff to Zamora and kill the nutraceutical boondoggle, focusing on becoming a legit biotech with real clinical trials (of course, we'll never know, since Furman might as well be a projection on a wall). Unfortunately, it appears that all he has done is create an unsustainable burn rate that funds accountants, with zero progress toward the only thing that matters in this strategy -- namely, doing the clinical trials. They seem to have no interest at all in explaining to shareholders what the hold-up on those is. Nor will they admit that they literally have zero chance of a valuation that would support a listing on a major exchange until they at least start them, rendering moot all the talk about creative ways to kickstart a NASDAQ listing. It's like 2+2 is supposed to equal 5 or something, and the world is supposed to accept that. None of this makes any sense. They've had a candidate cell therapy ready for testing for something like five years. It just doesn't add up.
